Turn Therapeutics (TTRX) Cash from Financing Activities (2024 - 2026)

Turn Therapeutics' Cash from Financing Activities history runs 3 years deep, the most recent figure standing at $7.8 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 680.14% year-over-year to $7.8 million in Q1 2026; TTM through Mar 2026 was $12.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $6.9 million, up 500.45% from the prior year.
• Cash from Financing Activities rose to $7.8 million in Q1 2026 per TTRX's latest filing, from $3.2 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $7.8 million in Q1 2026 and bottomed at $522206.0 in Q4 2024.
• The 3-year median for Cash from Financing Activities is $2.1 million (2025), against an average of $3.1 million.
• Across the five-year window, Cash from Financing Activities soared 508.51% in 2025 and jumped 680.14% in 2026, its largest moves.
• Year by year, Cash from Financing Activities stood at $522206.0 in 2024, then surged by 508.51% to $3.2 million in 2025, then surged by 145.04% to $7.8 million in 2026.
• Per Business Quant, the three latest TTRX Cash from Financing Activities figures stand at $7.8 million (Q1 2026), $3.2 million (Q4 2025), and $998092.0 (Q1 2025).